Monoclonal Antibodies in headache : from bench to patient / / Antoinette Massen van den Brink, Paolo Martelletti, editors

• Pubblicazione: Cham, Switzerland : , : Springer, , [2021]; ©2021
• Descrizione fisica: 1 online resource (176 pages)
• Disciplina: 616.047
• Soggetto topico: Headache - Treatment; Cefalàlgia; Terapèutica
• Soggetto genere / forma: Llibres electrònics
• Persona (resp. second.): Maassen van den BrinkAntoinette; MartellettiPaolo
• Nota di contenuto: Intro -- Foreword -- Preface -- Contents -- Chapter 1: The CGRP Family of Neuropeptides and their Receptors in the Trigeminovascular System -- 1.1 Introduction -- 1.2 The Receptors of the CGRP Family -- 1.3 The CGRP Family of Ligands and their Distribution -- 1.4 Relation Between Expression of Ligands and Receptors -- 1.4.1 Ligand Experiments -- 1.4.2 Receptor Expressions -- 1.4.3 Ligand/Receptor Expression -- 1.5 Conclusion -- References -- Chapter 2: Pharmacology -- Where Do the mAbs Act, Gepants Versus mAbs -- 2.1 Pharmacology -- 2.2 Gepants -- 2.3 mAbs Targeting the CGRPergic System -- 2.4 Conclusions -- References -- Chapter 3: Monoclonal Antibody Biology -- 3.1 Introduction -- 3.2 Structural Features of Antibodies -- 3.3 Therapeutic Antibody Types -- 3.4 Monoclonal Antibody Nomenclature -- 3.5 Pharmacodynamics (PD) and Pharmacokinetics (PK) -- 3.5.1 Absorption -- 3.5.2 Distribution -- 3.5.3 Elimination -- 3.6 Safety and Immunogenicity -- 3.7 Conclusion -- References -- Chapter 4: Guidelines for Clinical Trials -- 4.1 Patient Selection -- 4.1.1 Headache Definition -- 4.1.2 Age and Sex -- 4.1.3 Comorbidities and Concomitant Medications -- 4.1.4 Headache Onset and Duration -- 4.1.5 Previous Treatments -- 4.2 Operating Procedures -- 4.2.1 The Issue of Comparison with Placebo -- 4.2.2 Screening and Baseline Phase -- 4.2.3 Trial Duration -- 4.2.4 Open-Label Extensions -- 4.3 Endpoint Assessment -- 4.3.1 Definitions -- 4.3.1.1 Migraine Day -- 4.3.1.2 Headache Day -- 4.3.1.3 Responder Rate -- 4.3.2 Headache-Related Endpoints -- 4.3.3 Assessment Timepoints -- 4.3.4 Acute Medication Use -- 4.3.5 Patient-Reported Outcomes -- 4.3.6 Adverse Events -- 4.4 The Issues of Cluster Headache Trials -- 4.5 Conclusions and Future Perspectives -- References -- Chapter 5: Human Models -- 5.1 Introduction -- 5.2 Evidence of CGRP Involvement in Migraine Induction. ; 5.3 Mechanisms of CGRP-Induced Migraine Attacks -- 5.4 cAMP and cGMP Molecular Signaling Pathway -- 5.5 CGRP Models for Drug Testing -- 5.6 Future Perspectives and Conclusion -- Glossary -- References -- Chapter 6: CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- 6.1 Introduction -- 6.2 Animal Models of Primary Headaches -- 6.2.1 Animal Models of Migraine -- 6.2.1.1 Peripheral Models -- Nitroglycerin-Induced Model -- Models Induced by Peripheral Injection of CGRP -- Models Induced by Electrical Stimulation of TG -- Models Induced by Activation of Meninges -- Electrical or Mechanical Stimulation of Meninges -- Transient Receptor Potential (TRP) Channel Activation -- Dural Inflammation and Decreased Dural pH -- 6.2.1.2 Central Models -- Models Induced by Central Injection of CGRP -- 6.2.1.3 Other Models -- Models of Cortical Spreading Depression (CSD) -- The Spontaneous Trigeminal Allodynia (STA) Model -- Models Induced by Sleep Deprivation and Stress -- 6.3 Animal Models of Secondary Headaches -- 6.3.1 Post-Traumatic Headache (PTH) -- 6.3.2 Medication Overuse Headache (MOH) -- 6.4 Conclusion and Future Directions -- References -- Chapter 7: Galcanezumab -- 7.1 Therapeutic Indication -- 7.2 Mode of Action -- 7.3 Preclinical Trials -- 7.4 Phase II Clinical Trial Program for the Prevention of Migraine -- 7.5 Phase III Registration Trials for the Prevention of Episodic Migraine -- 7.6 Phase III Registration Trials for the Prevention of Chronic Migraine -- 7.7 CONQUER-A Phase IIIb Clinical Trial in a Difficult-to-Treat Cohort -- 7.8 Functional Improvement with Galcanezumab -- References -- Chapter 8: Eptinezumab -- 8.1 Introduction -- 8.2 Development -- 8.3 Administration -- 8.4 Pharmacokinetics -- 8.5 Pharmacodynamics and Mechanism of Action -- 8.6 Eptinezumab Clinical Trials -- 8.7 Conclusion -- References. ; Chapter 9: Erenumab -- 9.1 General -- 9.2 Compelling Evidence from Randomized Clinical Trials -- 9.3 Sustained Efficacy and Safety in Open-Label Extension Studies -- 9.4 Difficult-to-Treat Patients -- 9.5 Postmarketing Safety Data -- 9.6 Real-World Clinical Experience -- 9.7 Future Perspectives -- References -- Glossary -- Chapter 10: Fremanezumab -- 10.1 Introduction to the Compound -- 10.2 Chemistry -- 10.3 Fremanezumab Pharmacodynamics and Pharmacokinetics -- 10.4 Fremanezumab Clinical Efficacy -- 10.5 Fremanezumab Safety and Tolerability -- 10.6 Ongoing Trials -- 10.7 Conclusion -- References -- Chapter 11: Potential Side Effects and Pregnancy -- 11.1 Introduction -- 11.2 CGRP and (Patho)Physiology -- 11.2.1 CGRP and Cardiovascular System -- 11.2.2 CGRP, Inflammation, and Wound Healing -- 11.2.3 CGRP and the Gastrointestinal System -- 11.2.4 CGRP and the Central Nervous System -- 11.2.5 CGRP and Other Receptors -- 11.3 CGRP and Pregnancy -- 11.3.1 Pregnancy and CGRP (Receptor)-Antibodies -- 11.4 Conclusion -- References -- Chapter 12: Real-World Data, Clinical Practice So Far -- 12.1 Introduction -- 12.2 Design of the Observational Studies -- 12.2.1 Selection Criteria -- 12.2.1.1 Inclusion Criteria -- 12.2.1.2 Exclusion Criteria and Study Failure -- 12.2.2 Dosage -- 12.2.3 Outcomes of the Studies -- 12.2.3.1 Monthly Migraine, Monthly Headache Days, and Responder Rate -- 12.2.3.2 Monthly Acute Medication Consumption -- 12.2.3.3 Disability, Comorbidities, and Patient-Reported Outcomes -- 12.2.3.4 Assessment Time Points -- 12.3 Patients' Baseline Characteristics -- 12.4 Results -- 12.4.1 Erenumab -- 12.4.1.1 Efficacy -- Monthly Migraine Days and Responder Rate -- Acute Medications Consumption and Medication Overuse -- HIT-6 and Other Scales -- 12.4.1.2 Safety -- 12.4.2 Galcanezumab -- 12.4.2.1 Efficacy -- 12.4.2.2 Safety -- 12.5 Case Reports. ; 12.6 Limitations -- 12.7 Conclusions and Further Perspectives -- References -- Chapter 13: Migraine Versus Cluster Headache and Potential Other Indications -- 13.1 Introduction -- 13.2 Migraine -- 13.3 Cluster Headache -- 13.4 Persistent Post-Traumatic Headache -- References.
• Titolo autorizzato: Monoclonal Antibodies in headache
• ISBN: 3-030-69032-6
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910483537303321
• Lo trovi qui: Univ. Federico II
• Serie: Headache